studies on glp 1 GLP-1 weight loss drugs leave users low key nutrients, study finds Exploring the Side Effects of

Some are used off-label and are prepared by licensed U.S

Other potential side effects include injection site reactions, pancreatitis, gallbladder disease such as cholelithiasis, and a theoretical increased risk for thyroid C-cell tumors, although human data have not corroborated this risk

Forest plot analysis revealed significant improvements in menstrual frequency across all active interventions compared to placebo: GLP-1 RAs demonstrated a WMD of 3.58 (95% CI 3.54, 4.16), metformin showed a WMD of 3.76 (95% CI 3.42, 4.1), GLP-1 RAs/metformin combination achieved a WMD of 3.95 (95% CI 3.48, 4.42), and roflumilast exhibited a WMD of 3.99 (95% CI 3.63, 4.35) (Fig

This approval expands treatment options for patients living with diabetes in India

Improved cellular delivery of antisense oligonucleotide for miRNA-21 imaging in vivo using cell-penetrating peptide-based nanoprobes